Business Wire

CA-ANDERSEN-GLOBAL

31.1.2024 18:16:28 CET | Business Wire | Pressemeddelelse

Del
Andersen udvider værdiansættelseskapaciteten i Latinamerika med tilføjelser i Argentina, Chile, Colombia og Mexico

Andersen, den hurtigst voksende uafhængige, multidisciplinære serviceorganisation i verden, har udvidet sin værdiansættelseskapacitet og sit team med tilføjelsen af samarbejdsvirksomheder i Argentina, Chile, Colombia og Mexico. Bekendtgørelsen finder sted i forlængelse af lanceringen af Andersens globale værdiansættelsespraksis og tilføjelsen af værdiansættelseskapaciteter i Brasilien sidste år. Disse tilføjelser styrker organisationens hurtigt voksende platform i regionen, som allerede udbyder skattemæssig og juridisk dækning i mere end 18 lande i hele Latinamerika.

De nye firmaer, der slutter sig til Andersens platform i Latinamerika, inkluderer:

  • First Capital Group (Argentina) – First Capital Group har base i Buenos Aires og er et team af finansfolk med over 30 års erfaring i at levere forretningsmæssige og finansielle løsninger, herunder værdiansættelsesydelser.
  • Valoriza (Chile) – Med kontorer i Santiago og Miami er Valoriza et uafhængigt firma, der leverer grundige og indsigtsfulde værdiansættelser med fokus på værdiansættelse af virksomheder og M&A for det mellemstore marked.
  • Valuaciones de Chile (Chile) – Valuaciones de Chile har base i Santiago og leverer uafhængige værdiansættelsestjenester med fokus på fast ejendom, aktiver samt maskiner og udstyr.
  • Confianza (Colombia) – Confianza holder til i Bogota, har specialiseret sig i værdiansættelser af maskiner og udstyr og giver kunder i Latinamerika omfattende støtte til deres finansielle aktiviteter.
  • Giron Valuation Services (Mexico) – Giron Valuation Services (GVS), der opererer fra Estado de México, er et team af fagfolk med stor erfaring i at levere værdiansættelser af virksomheder og økonomisk rådgivning til både lokale og globale kunder.

"Værdiansættelse er et vigtigt vækstområde for Andersen, og man kan forvente at se os udvide vores globale værdiansættelsespraksis hastigt på andre vigtige markeder i Latinamerika og globalt," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktør for Andersen.

"Vi er stolte over at arbejde sammen med disse firmaer, når vi udvider vores globale værdiansættelsesservice i Latinamerika," tilføjer Sid Luckenbach, administrerende direktør for Andersens globale værdiansættelsespraksis. "Disse nye firmaer er et stærkt kulturelt match for Andersen og deler vores forpligtelse på uafhængighed, problemfri kundeservice, forvaltning og ekspertise."

Andersens globale værdiansættelsesteam samarbejder med virksomheder, fonde, velhavende privatpersoner og familiekontorer om værdiansættelse af virksomheder, materielle og immaterielle aktiver og komplekse værdipapirer med henblik på skat, finansiel rapportering og transaktionsrådgivning. Andersens kunder spænder over en række brancher med forskellige værdiansættelsesbehov på globalt plan.

"Latinamerika er fortsat et spændende vækstmarked for os," siger Leonardo Mesquita, Andersens regionale administrerende direktør for Latinamerika. "Vores kunder kræver i stigende grad uafhængige værdiansættelser i hele regionen, og vi ser frem til at opfylde deres værdiansættelsesbehov som ét firma."

Andersens globale værdiansættelsespraksis er repræsenteret i mere end 25 lande i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.

Om Andersen :

Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skatteeksperter og -jurister i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 15.000 eksperter i hele verden og en tilstedeværelse på over 425 lokaliteter gennem sine medlems- og samarbejdsvirksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240130606657/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye